China's Brii jumps most in near 8 months on commercial launch of COVID therapy

Brii Biosciences

07/07/2022 04:32

** Shares of China's infectious diseases therapies developer
Brii Biosciences Ltd  2137.HK  jump as much as 30.2% to
HK$11.50, the biggest daily pct rise since Nov. 15, if gains
hold.
    ** Stock hits the highest since April 14 and on track for a
second session of gain; it is also the biggest percentage gainer
on the Hang Seng Composite Index  .HSCI .
    ** Beijing-based Brii and its majority-owned joint venture
TSB Therapeutics (Beijing) Co Ltd announce the commercial launch
of a long-acting COVID-19 neutralizing antibody therapy, the
amubarvimab/romlusevimab combination, in China.  urn:newsml:reuters.com:*:nFWN2YN1JM
    ** Says the first commercial batch of the antibodies was
released on July 7, marking the commercialization of the
combination therapy.
    ** The Hang Seng Composite Index  .HSCI  slips 0.6%,
healthcare index  .HSCIH  falls 2% and Hang Seng Index  .HSI 
eases 0.5%
    ** As of last close, the stock had fallen 73.2% this year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))